Gongwin Biopharm Holdings Co., Ltd.

As of June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. carries a market capitalization of 8.44B, placing it among publicly traded companies globally. Its enterprise value stands at 6.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. has 121.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 200.88, and the price-to-book ratio stands at 3.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 163.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.92B versus a market cap of 8.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. maintains a current ratio of 8.19, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.45, indicating elevated leverage, while an interest coverage ratio of -56.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. posted a negative return on equity (ROE) of -6.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.16, reflecting losses generated across the asset base. The company generates approximately 1.14M in revenue per employee across its workforce of 37.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.84 indicates how many times Gongwin Biopharm Holdings Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. recorded 49,000.00 in income tax expense. The company reported a pretax loss of -176.12M and -164.52M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Gongwin Biopharm Holdings Co., Ltd.'s stock has gained approximately 20.02% over the past 52 weeks. The 50-day moving average sits at 121.98, while the 200-day moving average is 87.67.

Over the twelve months ended June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. generated 42.22M in revenue and converted that into -164.52M in net income, yielding earnings per share of -1.45. EBITDA reached -229.55M, while operating income came in at -242.65M.

As of June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. holds 1.67B in cash and equivalents against 149.93M in total debt, resulting in a net debt position of -627.59M. Total book value stands at 2.33B, with working capital of 1.51B providing operational flexibility.

Gongwin Biopharm Holdings Co., Ltd. produced -195.87M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.00M in capital expenditures, free cash flow totaled -198.88M - equivalent to -1.63 per share.

Over the twelve months ended June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. posted a gross margin of 63.09, reflecting its pricing power and cost economics. The operating margin of -574.67 and net profit margin of -389.63 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Gongwin Biopharm Holdings Co., Ltd. shareholders.

Gongwin Biopharm Holdings Co., Ltd.'s most recent stock split took place on July 20, 2022 with a 333:337 split ratio.

As of June 30, 2026, Gongwin Biopharm Holdings Co., Ltd. has an Altman Z-Score of 15.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.